louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01052974: Perioperative Analgesia by Femoral Perineural Catheter for Femoral Neck Fracture - Study KTcol
Official title: Perioperative Analgesia by Femoral Perineural Catheter for Femoral Neck Fracture - Study KTcol -
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Femoral Neck Fracture
Keywords: femoral neck fracture
analgesia
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2010-01-21
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Therapeutic essay of phase IV, monocentric, prospective, randomized, in double-blind during 48 hours(then simple-blind),controlled by placebo.

Abstract:

The increasing incidence of the number of femoral neck fractures and the poor prognosis of this traumatological pathology involves an optimization of the diagnostic, therapeutic and analgesic care.

A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection ("single shot") of local anesthetic with the technique of the femoral or iliofascial block. Nevertheless the single injection of a dose of local anesthetic associated or not with analgesic adjuvants, due to their pharmacological properties, can't prolong the efficiency of the loco-regional analgesia more than 12 hours.

The aim of our study is to evaluate, in the patients admitted in emergencies for suspicion of femoral neck fractures, the perioperative efficiency of an analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo (physiological serum).


Eligibility criteria: Inclusion Criteria:

* femoral neck fracture

Exclusion Criteria:

* Contraindication with analgesia

Primary outcomes:
measure: evaluate, in the patients admitted in emergencies for suspicion of femoral neck fractures, the perioperative efficiency of an analgesic treatment using a femoral perineural catheter
timeFrame: from the hospital admission to 24h after surgical operation
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: UHAngers
Study officials:
affiliation: University Hospital, Angers
name: Guillaume BOUHOURS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Guay J, Kopp S. Peripheral nerve blocks for hip fractures in adults. Cochrane Database Syst Rev. 2020 Nov 25;11(11):CD001159. doi: 10.1002/14651858.CD001159.pub3.
Clinical trial NCT01667965: Use of a Video Decision Tool to Improve Informed Decision-Making in Hospitalized Patients Considering Palliative Radiation Therapy
Official title: Use of a Video Decision Tool to Improve Informed Decision-Making in Hospitalized Patients Considering Palliative Radiation Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Metastatic Cancer or Locally Advanced
Patients Receiving Palliative Radiation
Keywords: palliative radiation
12-172
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2012-08-17
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inpatients will be approached regarding study enrollment at the time that they are evaluated by the inpatient radiation oncology team for palliative radiation therapy.

Brief summary: The purpose of this study is to assess the effectiveness and acceptability of a recently created informative video geared for patients who have been evaluated by a radiation oncologist for palliative radiation therapy during a hospitalization at Memorial Sloan-Kettering Cancer Center. Palliative radiation therapy is radiation therapy that is given to patients with the purpose of easing symptoms from cancer. It is not given with the intent to cure the cancer. The video presents basic information about palliative radiation and palliative care.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Eligible for palliative radiation to the brain, spine, chest, abdomen, pelvis, skin, or bone as per the judgment of the radiation oncologist or nurse practitioner
* Patient is English-speaking and able to give informed consent and fill out study questionnaires
* Hospitalized at MSKCC
* Pathologically confirmed malignancy
* Cancer is metastatic or locally advanced, and is not curable
* Patients who may undergo radiation at a satellite facility are still eligible for protocol enrollment

Exclusion Criteria:

* Those who have seen the video beforehand

Primary outcomes:
measure: create an effective video decision aid
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Beryl McCormack, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05822765: Effect of Adrenaline Concentration on Intraoperative Hemodynamics of Liposuction Patients
Official title: Effect of Adrenaline Concentration in Tumescence Solution on Intraoperative Hemodynamics of Liposuction Patients: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Intraoperative Hemodynamics
Liposuction
Keywords: Adrenaline
Tumescence Solution
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
Collaborators: name: Benha University
First posted: 2023-04-21
Enrollment: 40
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Liposuction is a procedure that has emerged over the last 30 years as a method to remove subcutaneous fat for cosmetic purposes. Numerous liposuction techniques have been developed .Tumescent liposuction involves using large volumes of dilute local anesthetic and epinephrine to facilitate anesthesia and decrease blood loss. Questions remain about the appropriate dose of local anesthetic, the use of general anesthesia in liposuction, and the setting in which the chosen liposuction method is used. Adrenaline is the most commonly used vasoconstrictor, the recommended concentration in the tumescent solution is 0.25-1 mg/L depending on the tissue vascularity. In the more vascular tissues, the concentration is 1 mg/L and is decreased to 0.5 mg/L in the less vascular areas of the body. The dose should not exceed 50μg/kg. If the maximum dose is anticipated to exceed, the procedure should be done in several stages.


Eligibility criteria: Inclusion Criteria:

* ASA I patients
* scheduled for liposuction for abdomen and flanks and body contouring with liposuction

Exclusion Criteria:

* Bleeding disorders, anemia or hemoglobin level less than 11g/dl
* Cardiovascular diseases,
* Uncontrolled diabetes mellitus,
* Collagen disorders, and
* Pregnancy

Primary outcomes:
measure: Blood pressure
timeFrame: 4 hours
Secondary outcomes:
measure: Heart rate
timeFrame: 4 hours
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Neveen Kohaf
Study officials:
References:
Clinical trial NCT01034865: Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer
Official title: Risk Factors and Molecular Genomics for Hepatocellular Carcinoma in U.S. Patients With Chronic Liver Disease: A Case Control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Hepatocellular
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2009-12-18
Enrollment: 750
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: For Experimental Subjects Only:

Patients with HCC

For Controls Only:

Patients with chronic liver disease without evidence of HCC

Brief summary: To identify risk factors for the development and diagnosis of hepatocellular CA in patients with chronic hepatitis C and to use the data to ultimately develop an effective screening program.


Eligibility criteria: Inclusion Criteria:

* For both experimental subjects and controls:

  1. Patients between older than 18 years of age of all ethnic backgrounds and genders.
  2. Patients with chronic liver disease
* For Experimental Subjects Only:

  1. Patients with HCC with a hepatic mass larger or equal to 5cm
  2. Patients with HCC with a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection
  3. Patients with HCC with a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.
* For Controls Only:

Patients with chronic liver disease without evidence of HCC confirmed by either :

1. A normal AFP level

2. a negative imaging study (ultrasound, CT, or MR imaging).

3. Negative liver cancer on explants.

\*Exclusion Criteria:

1. Patients who declined to participate in the study
2. Patients with a history of HIV infection
3. Patients with concurrent advanced malignancy of non-hepatic origin.
4. Patients with significant use of androgenic steroid.
5. Patients with exposure to vinyl chloride.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Mindie H. Nguyen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00217165: Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study
Official title: Taurine as an Anti-manic Agent: a Double-blind Placebo-controlled Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Bipolar Disorder
Mania
Bipolar Depression
Keywords: bipolar
mania
depression
taurine
alternative
Lead sponsor: Mclean Hospital
Sponsor class: OTHER
First posted: 2005-09-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 68
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the amino acid taurine has effects on mood stability in bipolar disorder.

Detailed description: Taurine is an amino acid that has some actions similar to mood stabilizers. Taurine is widely sold as a component of over-the-counter mood enhancing agents. However, controlled studies examining the mood effects of taurine are limited. An initial study in this laboratory looked at taurine's mood effects in individuals with bipolar disorder. This follow-up study is designed to further examine taurine's effects on manic symptoms. Subjects in the current follow-up study will add taurine or placebo to their current treatment regimen. Both depressive and manic symptoms will be tracked for three months to determine whether the addition of taurine affects mood symptoms.

Eligibility criteria: Inclusion Criteria:

bipolar disorder, type I bipolar disorder, type II mania hypomania mixed manic symptoms

Exclusion Criteria:

significant medical or psychiatric co-morbidity pregnancy or planning pregnancy current substance abuse or dependence

-

Primary outcomes:
measure: Scores on standardized measures of manic and depressive symptoms (HAM-D, MADRS, YMRS)
timeFrame: 12 weeks
Secondary outcomes:
measure: Side-effect ratings, general health ratings
timeFrame: 12 weeks
measure: Drop-outs due to medication changes
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Belmont
country: United States
facility: McLean Hospital
state: Massachusetts
Study officials:
affiliation: Mclean Hospital
name: Beth L Murphy, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05409365: Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
Official title: Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Verruca Vulgaris
Healthy
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2022-06-08
Enrollment: 50
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: primary care clinic

Brief summary: This study aims to assess the expression of SCCA2 in the skin of patients with warts and to detect its correlation with characteristics of warts.

Detailed description: Type of the study: Cross sectional study. Patients: This study will include 25 patients with verruca vulgaris and 25 healthy volunteers.

Inclusion criteria:

Patients present with warts (verruca vulgaris type).

Exclusion criteria:

Subjects who presenting with allergic diseases or other dermatological diseases or had a history of squamous cell carcinoma will be excluded from this study One skin biopsy will be taken from each healthy volunteers of the control group via 2-mm disposable punches under complete sterile precautions. Two biopsies will be taken from patients with wart lesion one from verruca vulgaris via 5-mm disposable punches and another from non-affected skin via 2-mm disposable punches under complete sterile precautions.

Biopsy handling: Each specimen in both groups will be fixed in formalin and embedded in paraffin to form paraffin blocks. Serial sections will be obtained from each block and stained with hematoxylin and eosin (H\&E) for histological diagnosis.

Stained sections will be examined under a light microscope. To confirm the diagnosis of wart, the grade of inflammation and the density of dermal inflammatory infiltrate will be classified as follows Grade 0, no infiltrate; Grade 1, mild; Grade 2, moderate; or Grade 3, marked infiltrate.

Immunohistochemical staining: investigators will use monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody). Immunohistochemical staining will be performed the pattern of immunostaining for SCCA2 will be evaluated in both the epidermis and dermis of wart lesions. The immunohistochemical score (IHC) range will be as follows: 0: negative expression of SCCA2; 1+: weak expression of SCCA2; 2+: moderate expression of SCCA2; and 3+: strong expression of SCCA2.

Eligibility criteria: Inclusion Criteria:

* Patients present with warts (verruca vulgaris type).

Exclusion Criteria:

* Subjects who presenting with allergic diseases or other dermatological diseases or had a history of squamous cell carcinoma will be excluded from this study.

Primary outcomes:
measure: Assessment of Squamous Cell Carcinoma Antigen2 in Verruca Vulgaris
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University
Study officials:
affiliation: Director
name: Ashraf Ahmed Abd El-Latif Abd El-Latif, Lecturer
role: STUDY_DIRECTOR
References:
Clinical trial NCT04444765: Hemodynamic and Respiratory Tolerance of Intermittent Hemodialysis in Critically Ill Patients
Official title: Hemodynamic and Respiratory Tolerance of Intermittent Hemodialysis (Acetate Free Biofiltration and Bicarbonate-based Intermittent Dialysis) in Critically Ill Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Kidney Injury
Keywords: Acute kidney injury
renal replacement therapy
acetate free biofiltration
bicarbonate-based hemodialysis
C02 removal
intensive care unit
critical care
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2020-06-24
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with acute kidney injury

Brief summary: Acute kidney injury (AKI) affects up to 30% of critically ill patients and is associated with increased rates of mortality. Up to 60% of patients with AKI will ultimately require renal replacement therapy (RRT). Intermittent hemodialysis (IHD) is one of the main methods of RRT worldwide. In IHD-bicar, dialysate is composed by electrolytes, including calcium, and bicarbonate. To avoid calcium carbonate precipitation, dialysate has to be supplemented with acids (citric acid, chloride acid or acetic acid). However, IHD-bicar may be associated with hemodynamic instability or respiratory intolerance, mainly related to the CO2 release in the circulation during IHD (HCO3- \<--\> CO2 + H2O). Some recent studies showed that acetate free biofiltration (AFB-K), a technique that does not require dialysate acidification, could be associated with better hemodynamic stability and to a lower amount of CO2 delivered to the patients. AFB-K may thus improve the hemodynamic and respiratory tolerance of intermittent RRT in critically ill patients.

Detailed description: In this prospective observational study, investigators aim to characterize the hemodynamic and respiratory tolerances of HDI-bicar and AFB-K in critically ill patients requiring RRT.

Eligibility criteria: Inclusion Criteria:

* Patients ≥ 18 years old
* Invasive monitoring of blood pressure
* Non opposition to the research
* Admission to the intensive care unit
* Need of intermittent hemodialysis

Exclusion Criteria:

* Sodium bicarbonate infusion
* Pregnancy or breastfeeding
* Juridical protection

Primary outcomes:
measure: Occurence of hemodynamic event
timeFrame: From admission to discharge, up to 4 hours
Secondary outcomes:
measure: Change in maximal PaCO2
timeFrame: 1 hour after the beginning of dialysis , up to 4 hours
measure: Maximum difference of tcPCO2 and etCO2
timeFrame: From admission to discharge, up to 4 hours
measure: Change in the "strong ion difference"
timeFrame: baseline, 4 hours
measure: Change in plasma pH
timeFrame: 1 hour after the beginning of dialysis session, up to 4 hours
Other outcomes:
Locations:
city: Toulouse
country: France
facility: Hôpital Rangueil
Study officials:
name: Stanislas Faguer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02564965: Endoscopic Large Caliber Drainage vs. Complete Necrosectomy for Treatment of Walled-off Pancreatic Necrosis
Official title: Endoscopic Large Caliber Drainage vs. Complete Necrosectomy for Treatment of Walled-off Pancreatic Necrosis: A Prospective, Randomized Noninferiority Trial.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Necrotizing Pancreatitis
Keywords: Acute Necrotizing Pancreatitis
Walled-Off Pancreatic Necrosis
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2015-10-01
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine optimal treatment strategies for symptomatic walled-off pancreatic necrosis( WON).


Eligibility criteria: Inclusion Criteria:

* Adult (\> 18 yo) patients
* With symptomatic walled- off pancreatic necrosis in which an endoscopic approach is appropriate based on cross-sectional imaging
* Must have solid necrotic material present in their pancreatic fluid collection as determined by MRI, EUS, or direct transluminal endoscopic imaging of the collection

Exclusion Criteria:

* Previous intervention for pancreatic necrosis (surgical, percutaneous, or endoscopic)
* Indication for emergency laparotomy (compartment syndrome, bowel ischemia, bleeding, or perforation of a GI lumen)
* Uncorrectable coagulopathy.

Primary outcomes:
measure: Complete resolution as defined by complete radiographic resolution of the walled-off necrosis (WON)
timeFrame: Baseline to 4 months after initiation of endoscopic treatment
Secondary outcomes:
measure: Clinical resolution of infection as defined by complete radiographic resolution and/or symptoms of pain and gastric outlet obstruction
timeFrame: Baseline to 4 months after initiation of endoscopic treatment
measure: Symptom resolution (Visual Analogue Scale for pain, gastric outlet obstruction, and weight gain)
timeFrame: Baseline to 4 months after initiation of endoscopic treatment
measure: Decrease in incidence of adverse events
timeFrame: Baseline to 4 months after initiation of endoscopic treatment
measure: Decrease in number of hospital days during treatment course
timeFrame: Baseline to 4 months after initiation of endoscopic treatment
measure: Decrease in total costs of pancreatitis-related health care during treatment course
timeFrame: Baseline to 4 months after initiation of endoscopic treatment
Other outcomes:
Locations:
Study officials:
affiliation: Mayo Clinic
name: Barham Abu Dayyeh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01172665: Celiac Disease Database
Official title: University of Chicago Celiac Disease Database
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Celiac Disease
Keywords: Celiac Disease
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2010-07-30
Enrollment: 1090
Sex: ALL
Minimum age (years): 0
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Both pediatric and adult patients of The University of Chicago Medical Center who have been diagnosed with celiac disease or gluten sensitivity.

Brief summary: The focus of this study is to create a database containing information about patients with celiac disease. This database will allow us to examine clinical and epidemiologic features of the University of Chicago Medical Center patient population. We have the largest population of patients with celiac disease in the mid-West and as such this study using information gathered from our database can greatly contribute to our current understanding of this disease.

Detailed description: This database will allow us to examine clinical and epidemiologic features of the University of Chicago Medical Center patient population.

Eligibility criteria: Inclusion Criteria:

* Must be a patient at The University of Chicago Medical Center
* Clinical diagnosis of celiac disease or gluten sensitivity

Exclusion Criteria:

* Currently being treated at a healthcare facility other than The University of Chicago Medical Center
* Not diagnosed with celiac disease or gluten sensitivity

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago Medical Center
state: Illinois
Study officials:
affiliation: University of Chicago
name: Ritu Verma, MD
role: PRINCIPAL_INVESTIGATOR
References: